Latest Headlines

  1. Lab-On-A-Chip Platform Shows How Immune Cells Attack Cancer Cells 6/18/2026

    Immunotherapies are a promising approach in the fight against cancer. Researchers at the Technical University of Munich (TUM) have developed a lab-on-a-chip system called CellTrap.

  2. Proscia Launches Fifth Generation Of Concentriq, Bringing The Latest Advancements In AI To Pathologists And Scientists 6/17/2026

    Proscia today introduced the Fifth Generation of its Concentriq[1] platform, helping pathologists focus on high-judgment decisions and enabling scientists to quickly move from early signals to evidence-based program decisions. Proscia is trusted by diagnostic laboratories that manage 12 million patient cases annually, and 16 of the top 20 pharmaceutical companies.

  3. Sysmex launches HISCL Platform, Enabling Faster, Scalable Alzheimer's Blood Testing 6/17/2026

    Independent European studies presented at CTAD 2025 and ADPD2026 confirmed that the HISCL p-Tau217 RUO* and the HISCL Aβ42/40 ratio are highly accurate for early identification of Aβ pathology.

  4. Autism Diagnostics Lab Announces The U.S. Launch Of The First Commercial Urine-Based Microbial-Derived Metabolite (MDM™) Gut & Brain Health Test For Autism Screening 6/17/2026

    Autism Diagnostics Lab, a precision diagnostics company developing innovative and metabolomics-based tests designed to enable earlier autism detection, empower clinical decision-making, and improve outcomes for individuals with autism and their families, today announced the U.S. launch of the MDM™ Gut & Brain Health Test, the first commercial urine-based autism screening tool developed from research conducted at Arizona State University and published in Molecular Psychiatry, a Nature journal, identifying a distinct autism-associated biological signature measurable through a simple urine sample.

  5. Validated Monospecific Recombinant And Monoclonal Antibodies 6/16/2026

    Amsbio has expanded its diverse range of recombinant and monoclonal antibodies to include over 10,000 new validated monospecific products in 15,000 formulations to support research in cancer, immunology, neuroscience, and signal transduction.

  6. Cizzle Bio Announces Laboratory Validation Of CIZ1B Biomarker Blood Test For Early Lung Cancer At OmniHealth Diagnostics 6/16/2026

    Cizzle Bio, Inc., a Texas-based biotechnology company advancing biomarker blood tests for early detection of lung and gastric cancers, today announced the laboratory validation of its proprietary CIZ1B biomarker blood test for early lung cancer at OmniHealth Diagnostics, a CLIA-certified, COLA-accredited clinical laboratory based in Dallas and a member of the Katharos Health family of laboratories.

  7. Paramount Diagnostics Lab Selects Abluva To Strengthen Data Security And Compliance Across Its Clinical Operations 6/16/2026

    Paramount Diagnostics Lab (Paramount Diagnostic Laboratory LLC), a New Jersey-based clinical diagnostics provider, and Abluva, a Data Runtime Security company headquartered in Palo Alto, California, today announced that Paramount has selected Abluva’s Data Runtime Security platform to protect patient data in real time across its clinical operations.

  8. KAUST Researchers Develop Technology That Could Make Cancer Diagnosis Faster 6/15/2026

    Scientists at King Abdullah University of Science and Technology (KAUST) have developed a new stain-free imaging platform designed to analyze tissue samples more quickly and consistently, supporting future AI-assisted cancer diagnostics. 

  9. QIAGEN Expands QIAcuity Gene Expression Portfolio To Accelerate Digital PCR Adoption Across Research And Biopharma 6/15/2026

    QIAGEN N.V. today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications.

  10. Behemoth Labz Introduces Insights Into Growing Demand For COA Tested SARMs And Peptides In Research Applications 6/12/2026

    Behemoth Labz has introduced new insights regarding increasing demand for Certificate of Analysis (COA)-tested SARMs and Peptides within research-focused markets.